Is the brand name of acotinib/acalabrutinib Concosti?

Acalabrutinib/The trade name of Acalabrutinib is Concoci. In China, it received marketing approval for the first time on May 26, 2023. It is currently indicated for the treatment of adult patients with mantle cell lymphoma (MCL) who have received at least one prior therapy. It was also recently approved in the United States for the treatment of chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). It belongs to a class of drugs called BTK inhibitors, which can prevent the growth and spread of malignant tumor cells by inhibiting the B-cell receptor tyrosine kinase (BTK).

Acalabrutinib is a targeted therapy drug used to inhibit the function of Bruton's tyrosine kinase (BTK). BTK plays an important role in B cell signaling, especially in some B cell lymphomas, where overactivity of BTK may promote tumor cell proliferation and survival. By inhibiting the function of BTK, acalabrutinib can effectively block this signaling pathway, thereby achieving the purpose of treating cancer. The emergence of acotinib provides new treatment options for these patients and is expected to improve their survival conditions and quality of life.

In terms of usage and dosage, Kangcoqi needs to be taken according to the doctor's instructions. The specific dosage and course of treatment will be adjusted according to the patient's specific conditions. At the same time, patients also need to pay attention to possible adverse reactions caused by drugs, such as bleeding, infection, diarrhea, etc. If serious adverse reactions occur, they should seek medical treatment in time.

In general, Concordi (acolitinib) is a targeted treatment drug for certain diseases in adults. It inhibitsBTK function and blocks the proliferation and survival of tumor cells, providing patients with new treatment hope. However, the use of the drug needs to be under the guidance of a doctor to ensure its safety and effectiveness.